Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025

非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望

◆タイトル:Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
◆商品コード:VGAIN5112511
◆調査・発行会社:visiongain
◆発行日:2015年10月
◆ページ数:172
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、非小細胞肺がん(NSCLC)治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・非小細胞肺がん(NSCLC)治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・非小細胞肺がん(NSCLC)治療薬の世界市場:主要な医薬品分析
・非小細胞肺がん(NSCLC)治療薬の世界市場:研究開発パイプライン
・非小細胞肺がん(NSCLC)治療薬の世界市場:セグメント別市場分析
・非小細胞肺がん(NSCLC)治療薬の世界市場:地域別市場分析、市場規模予測
・非小細胞肺がん(NSCLC)治療薬の世界市場:環境分析
・非小細胞肺がん(NSCLC)治療薬の世界市場:専門家の見解
・非小細胞肺がん(NSCLC)治療薬の世界市場:主要企業分析
・結論

Non-Small Cell Lung Cancer – Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities
Are you interested in the future of lung cancer treatments? Our new analysis forecasts drug revenues for non-small cell lung cancer (NSCLC). There you find outlooks for sales growth. You also explore trends, results, R&D and opportunities, seeing commercial prospects.

Visiongain’s report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and revenues those cancer drugs can achieve.

Read on, then, to explore that industry for lung cancer therapies and see what future revenue its expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions
The future looks promising for pharma companies treating those pulmonary cancers. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2015, what revenues and other progress are possible.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing outlooks. You also gain 83 tables, 49 charts and an interview with Novartis.

Our study’s purpose is to help your research, analyses and decisions on non-small cell lung cancer, also benefiting your authority and reputation for commercial insight. Stay ahead.

Although no single report covers everything, the following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for treating that lung cancer
Discover in our new analysis revenue predictions to 2025 for NSCLC submarkets at world level. See what is possible for these four therapeutic classes:
• Chemotherapies
• EGFR and ALK inhibitors
• VEGF and VEGFR agents
• Immunotherapy.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors’ actions and outlooks.

That way you see how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a rising incidence of those lung cancers, the demand for better treatments will continue to bolster that industry and market. Discover what is possible.

You also find sales forecasts by product, exploring how those agents can succeed.

Predictions of leading products’ sales – what is possible for those cancer-treating drugs?
How will individual NSCLC medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of these 11 brands:
• Alimta (pemetrexed) by Eli Lilly
• Avastin (bevacizumab) by Roche
• Tarceva (erlotinib) by Roche
• Iressa (gefitinib) by AstraZeneca
• Gilotrif (afatinib) by Boehringer Ingelheim
• Xalkori (crizotinib) by Pfizer
• Abraxane (paclitaxel Protein-Bound) by Celgene
• Taxotere (docetaxel) by Sanofi
• Cyramza (ramucirumab) by Eli Lilly
• Zykadia (ceritinib) by Novartis
• Opdivo (nivolumab) by Bristol-Myers Squibb.

There you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating non-small cell lung cancer. Our work also shows you geographical predictions, by country.

National markets – what outlooks for those anticancer drug revenues?
Advances in the biopharma industry expand the range and use of medicines to treat NSCLC in developed and developing countries. Our work shows you individual revenue forecasts to 2025 for 11 national markets:
• The United States
• Japan
• Germany, France, the United Kingdom, Italy and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

That way you assess regions with highest revenues and potential sales growth. Explore outlooks for treating those diseases, including patients’ and healthcare providers’ needs.

You also examine developments leading to novel and improved NSCLC treatments.

R&D for those anticancer medicines – trends, innovations and progress
In our study you investigate that oncology – research and development on that pulmonary disease. You examine technological advances, exploring clinical trials and what they mean.

There, in particular, you find discussions of nine R&D pipeline candidates for non-small cell lung cancer:
• Alecensa (alectinib) by Roche
• Vargatef (nintedanib) by Boehringer Ingelheim
• AZD9291 by AstraZeneca
• Rociletinib (CO-1686) by Clovis Oncology
• Keytruda (pembrolizumab) by Merck (MSD)
• Ganetespib (STA-9090) by Synta Pharmaceuticals
• Halaven (eribulin) by Eisai
• Necitumumab by Eli Lilly
• Atezolizumab (MPDL3280A) by Roche.

【レポートの目次】

1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2015-2025
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025

4. NSCLC R&D Pipeline, 2015-2025
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2015-2025
5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025

7. Research Interview
7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future

8. Conclusions from Our Research and Analysis
8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks

List of Tables
Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Example NSCLC First-Line Therapy Options for the Different Patient Populations
Table 3.1 FDA-Approved Indications for Alimta, 2004-2009
Table 3.2 Patent Expiries for Alimta, 2015-2022
Table 3.3 Total Alimta Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.4 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.5 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.6 FDA-Approved Indications for Avastin, 2004-2014
Table 3.7 Total Avastin Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.8 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.9 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.10 FDA-Approved Indications for Tarceva, 2004-2013
Table 3.11 Total Tarceva Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.12 Tarceva NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.13 Tarceva for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.14 Total Iressa Revenues ($bn), 2010-2014
Table 3.15 Iressa NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.16 Iressa for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.17 Gilotrif NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.18 Gilotrif for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.19 Total Xalkori Revenues ($bn), AGR (%), CAGR (%), 2012-2014
Table 3.20 Xalkori NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.21 Xalkori for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.22 FDA-Approved Indications for Abraxane, 2005-2013
Table 3.23 Total Abraxane Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.24 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.25 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.26 FDA-Approved Indications for Taxotere, 1999-2006
Table 3.27 Total Taxotere Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.28 Taxotere NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.29 Taxotere for NSCLC Forecast: Revenues ($bn), AGR (%),CAGR (%), 2020-2025
Table 3.30 FDA-Approved Indications for Cyramza, 2014-2015
Table 3.31 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.32 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.33 FDA-Approved Indications for Abraxane, 1996-2006
Table 3.34 Zykadia NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.35 Zykadia for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.36 Opdivo NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.37 Opdivo for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 4.1 Currently Ongoing Clinical Trials Involving Alectinib in NSCLC
Table 4.2 Selected Ongoing Clinical Trials Involving Vargatef in NSCLC
Table 4.3 Selected Ongoing Clinical Trials Involving AZD9291 in NSCLC
Table 4.4 Ongoing Clinical Trials Involving Rociletinib in NSCLC
Table 4.5 Selected Ongoing Clinical Trials Involving Keytruda in NSCLC
Table 4.6 Ongoing Clinical Trials Involving Ganetespib in NSCLC
Table 4.7 Clinical Trials Involving Halaven in NSCLC
Table 4.8 Selected Ongoing Clinical Trials Involving Necitumumab in NSCLC
Table 4.9 Ongoing Clinical Trials Involving Atezolizumab in NSCLC
Table 5.1 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 5.2 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 6.1 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.2 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.3 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.4 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.6 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.7 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.8 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.9 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.10 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.11 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.12 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.13 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.14 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.15 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.16 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.17 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.18 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.19 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.20 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.21 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.22 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.23 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.24 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.25 Japanese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.26 Japanese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.27 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.28 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.29 Brazilian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.30 Brazilian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.31 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.32 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.33 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.34 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025

List of Figures
Figure 2.1 Example Adjuvant Chemotherapy Regimens for NSCLC in Stage 1 or Stage 2
Figure 2.2 Example Chemotherapy Regimens for Use in Concurrent Chemotherapy / Radiation in Stage 3 NSCLC
Figure 2.3 Example Chemotherapy Regimens for use in Stage 4 NSCLC
Figure 3.1 Total Alimta Revenues ($bn), 2010-2014
Figure 3.2 Alimta for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.3 Total Avastin Revenues ($bn), 2010-2014
Figure 3.4 Avastin for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.5 Total Tarceva Revenues ($bn), 2010-2014
Figure 3.6 Tarceva for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.7 Total Iressa Revenues ($bn), 2010-2014
Figure 3.8 Iressa Revenues Regional Breakdown: Revenues ($bn), Market Share (%), 2014
Figure 3.9 Iressa for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.10 Gilotrif for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.11 Total Xalkori Revenues ($bn), 2012-2014
Figure 3.12 Xalkori for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.13 Total Abraxane Revenues ($bn), 2010-2014
Figure 3.14 Abraxane for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.15 Total Taxotere Revenues ($bn), 2010-2014
Figure 3.16 Taxotere for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.17 Cyramza for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.18 Zykadia for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.19 Opdivo for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 5.1 Global NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 5.2 SWOT Analysis of Global NSCLC Market, 2015
Figure 6.1 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2015
Figure 6.2 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2025
Figure 6.3 Therapeutic Segments within the NSCLC Market: Revenues ($bn), 2015-2025
Figure 6.4 Chemotherapy Segment: Revenues ($bn), 2015-2025
Figure 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), 2015-2025
Figure 6.6 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), 2015-2025
Figure 6.7 Immunotherapy Segment: Revenues ($bn), 2015-2025
Figure 6.8 Regional Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2015
Figure 6.9 Regional Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2025
Figure 6.10 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), 2015-2025
Figure 6.11 US NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.12 German NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.13 French NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.14 Italian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.15 UK NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.16 Spanish NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.17 Japanese NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.18 Chinese NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.19 Brazilian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.20 Russian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.21 Indian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 8.1 Global NSCLC Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2015-2025
Figure 8.2 Breakdown by Submarket: Revenues ($bn), 2015-2025
Figure 8.3 Leading National Markets: Revenues ($bn), 2014
Figure 8.4 Leading National Markets: Revenues ($bn), 2025

【レポートのキーワード】

非小細胞肺がん(NSCLC)、非小細胞肺がん治療薬、医薬品、研究開発

★調査レポート[非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望] ( Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025 / VGAIN5112511) 販売に関する免責事項
[非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望] ( Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025 / VGAIN5112511) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆